1Ph.D. Scholar, Dept. of Shalakya Tantra, Parul Institute of Ayurveda, Vadodara, Gujarat
2HoD, Dept. of Shalakya Tantra, Parul Institute of Ayurveda, Vadodara, Gujarat
3Associate professor, Department of PTSR, FIMS, SGT University, Haryana
4Associate professor, Department of Shalya Tantra, FIMS, SGT University, Haryana
Background: Migraine is a prevalent neurological disorder with significant impact on daily productivity and quality of life. Many individuals experience over 50% reduction in work, academic, or household efficiency during attacks. The search for safe and effective alternatives has prompted exploration of traditional Ayurvedic interventions.
Objective: To evaluate the clinical efficacy of Vacha Pippali Taila Nasya in combination with Pathyashadangam Kashaya for the management of Ardhavabhedaka (migraine).
Methods: A total of 10 patients diagnosed with Ardhavabhedaka were enrolled from the OPD of Shalakya Tantra, SGT Ayurveda College and Hospital. Patients received Vacha Pippali Taila Nasya and Pathyashadangam Kashaya for 28 days, with follow-up assessments on days 15, 30, and 60. Outcome measures included HIT-6, MIDAS, and symptom severity scores. Statistical analysis was conducted using paired t-tests, Wilcoxon signed-rank tests, and Friedman tests, as appropriate.
Results: Significant improvements were observed in headache severity, nausea/vomiting, and photophobia/phonophobia scores (p<0.05). Mean HIT-6 and MIDAS scores showed reductions, though not statistically significant. No major adverse effects were reported.
Conclusion: The combination of Vacha Pippali Taila Nasya and Pathyashadangam Kashaya may offer a safe and beneficial approach for reducing migraine symptoms, warranting further investigation in larger controlled trials.
Keywords: Pathyashadangam Kashaya, Vacha Pippali Taila, Migraine, Ardhavabhedaka.
How to cite this article: Bamola P, Keskar M, Gupta H, Gupta S. Efficacy Of Vacha Pippali Taila Nasya And Pathyashadangam Kashaya In The Management Of Ardhavabhedaka (Migraine): A Pilot Clinical Study. Int J Drug Deliv Technol. 2026;16(15s): 10-15. DOI: 10.25258/ijddt.16.15s.2
Source of support: Nil.
Conflict of interest: None